The Qantas board has avoided a second strike on its remuneration report as its share price hit a record so Mahnaz Angury spoke with Upstream Aviation Analyst Tim Collins to find out if its reputation is being repaired; Rhayna Bosch discusses the future of AI and the implication of GLP-1 drugs like Ozempic with ResMed CEO Michael Farrell; and SBS Finance Editor Ricardo Gonçalves looks through the day's market news with Isaac Poole from Oreana Group.
Listen to Australian and world news, and follow trending topics with SBS News Podcasts.
Share
